Cargando…

TLR4 Deficiency Protects against Hepatic Fibrosis and Diethylnitrosamine-Induced Pre-Carcinogenic Liver Injury in Fibrotic Liver

BACKGROUND: The development of hepatocellular carcinoma (HCC) is a common consequence of advanced liver fibrosis but the interactions between fibrogenesis and carcinogenesis are still poorly understood. Recently it has been shown that HCC promotion depends on Toll-like receptor (TLR) 4. Pre-cancerog...

Descripción completa

Detalles Bibliográficos
Autores principales: Weber, Susanne Nicole, Bohner, Annika, Dapito, Dianne H., Schwabe, Robert F., Lammert, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938399/
https://www.ncbi.nlm.nih.gov/pubmed/27391331
http://dx.doi.org/10.1371/journal.pone.0158819
_version_ 1782441849109086208
author Weber, Susanne Nicole
Bohner, Annika
Dapito, Dianne H.
Schwabe, Robert F.
Lammert, Frank
author_facet Weber, Susanne Nicole
Bohner, Annika
Dapito, Dianne H.
Schwabe, Robert F.
Lammert, Frank
author_sort Weber, Susanne Nicole
collection PubMed
description BACKGROUND: The development of hepatocellular carcinoma (HCC) is a common consequence of advanced liver fibrosis but the interactions between fibrogenesis and carcinogenesis are still poorly understood. Recently it has been shown that HCC promotion depends on Toll-like receptor (TLR) 4. Pre-cancerogenous events can be modelled in mice by the administration of a single dose of diethylnitrosamine (DEN), with HCC formation depending amongst others on interleukin (IL) 6 production. Mice lacking the hepatocanalicular phosphatidylcholine transporter ABCB4 develop liver fibrosis spontaneously, resemble patients with sclerosing cholangitis due to mutations of the orthologous human gene, and represent a valid model to study tumour formation in pre-injured cholestatic liver. The aim of this study was to investigate DEN-induced liver injury in TLR4-deficient mice with biliary fibrosis. METHODS: ABCB4-deficient mice on the FVB/NJ genetic background were crossed to two distinct genetic backgrounds (TLR4-sufficient C3H/HeN and TLR4-deficient C3H/HeJ) for more than 10 generations. The two congenic knockout and the two corresponding wild-type mouse lines were treated with a single dose of DEN for 48 hours. Phenotypic differences were assessed by measuring hepatic collagen contents, inflammatory markers (ALT, CRP, IL6) as well as hepatic apoptosis (TUNEL) and proliferation (Ki67) rates. RESULTS: Hepatic collagen accumulation is significantly reduced in ABCB4(-/-):TLR4(-/-)double-deficient mice. After DEN challenge, apoptosis, proliferation and inflammatory markers are decreased in TLR4-deficient in comparison to TLR4-sufficient mice. When combining ABCB4 and TLR4 deficiency with DEN treatment, hepatic IL6 expression and proliferation rates are lowest in fibrotic livers from the double-deficient line. Consistent with these effects, selective digestive tract decontamination in ABCB4(-/-) mice also led to reduced tumor size and number after DEN. CONCLUSION: This study demonstrates that liver injury upon DEN challenge depends on pre-existing fibrosis and genetic background. The generation of ABCB4(-/): TLR4(-/-) double-deficient mice illustrates that TLR4-deficiency protects against hepatic injury in a preclinical mouse model of chronic liver disease.
format Online
Article
Text
id pubmed-4938399
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-49383992016-07-22 TLR4 Deficiency Protects against Hepatic Fibrosis and Diethylnitrosamine-Induced Pre-Carcinogenic Liver Injury in Fibrotic Liver Weber, Susanne Nicole Bohner, Annika Dapito, Dianne H. Schwabe, Robert F. Lammert, Frank PLoS One Research Article BACKGROUND: The development of hepatocellular carcinoma (HCC) is a common consequence of advanced liver fibrosis but the interactions between fibrogenesis and carcinogenesis are still poorly understood. Recently it has been shown that HCC promotion depends on Toll-like receptor (TLR) 4. Pre-cancerogenous events can be modelled in mice by the administration of a single dose of diethylnitrosamine (DEN), with HCC formation depending amongst others on interleukin (IL) 6 production. Mice lacking the hepatocanalicular phosphatidylcholine transporter ABCB4 develop liver fibrosis spontaneously, resemble patients with sclerosing cholangitis due to mutations of the orthologous human gene, and represent a valid model to study tumour formation in pre-injured cholestatic liver. The aim of this study was to investigate DEN-induced liver injury in TLR4-deficient mice with biliary fibrosis. METHODS: ABCB4-deficient mice on the FVB/NJ genetic background were crossed to two distinct genetic backgrounds (TLR4-sufficient C3H/HeN and TLR4-deficient C3H/HeJ) for more than 10 generations. The two congenic knockout and the two corresponding wild-type mouse lines were treated with a single dose of DEN for 48 hours. Phenotypic differences were assessed by measuring hepatic collagen contents, inflammatory markers (ALT, CRP, IL6) as well as hepatic apoptosis (TUNEL) and proliferation (Ki67) rates. RESULTS: Hepatic collagen accumulation is significantly reduced in ABCB4(-/-):TLR4(-/-)double-deficient mice. After DEN challenge, apoptosis, proliferation and inflammatory markers are decreased in TLR4-deficient in comparison to TLR4-sufficient mice. When combining ABCB4 and TLR4 deficiency with DEN treatment, hepatic IL6 expression and proliferation rates are lowest in fibrotic livers from the double-deficient line. Consistent with these effects, selective digestive tract decontamination in ABCB4(-/-) mice also led to reduced tumor size and number after DEN. CONCLUSION: This study demonstrates that liver injury upon DEN challenge depends on pre-existing fibrosis and genetic background. The generation of ABCB4(-/): TLR4(-/-) double-deficient mice illustrates that TLR4-deficiency protects against hepatic injury in a preclinical mouse model of chronic liver disease. Public Library of Science 2016-07-08 /pmc/articles/PMC4938399/ /pubmed/27391331 http://dx.doi.org/10.1371/journal.pone.0158819 Text en © 2016 Weber et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Weber, Susanne Nicole
Bohner, Annika
Dapito, Dianne H.
Schwabe, Robert F.
Lammert, Frank
TLR4 Deficiency Protects against Hepatic Fibrosis and Diethylnitrosamine-Induced Pre-Carcinogenic Liver Injury in Fibrotic Liver
title TLR4 Deficiency Protects against Hepatic Fibrosis and Diethylnitrosamine-Induced Pre-Carcinogenic Liver Injury in Fibrotic Liver
title_full TLR4 Deficiency Protects against Hepatic Fibrosis and Diethylnitrosamine-Induced Pre-Carcinogenic Liver Injury in Fibrotic Liver
title_fullStr TLR4 Deficiency Protects against Hepatic Fibrosis and Diethylnitrosamine-Induced Pre-Carcinogenic Liver Injury in Fibrotic Liver
title_full_unstemmed TLR4 Deficiency Protects against Hepatic Fibrosis and Diethylnitrosamine-Induced Pre-Carcinogenic Liver Injury in Fibrotic Liver
title_short TLR4 Deficiency Protects against Hepatic Fibrosis and Diethylnitrosamine-Induced Pre-Carcinogenic Liver Injury in Fibrotic Liver
title_sort tlr4 deficiency protects against hepatic fibrosis and diethylnitrosamine-induced pre-carcinogenic liver injury in fibrotic liver
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938399/
https://www.ncbi.nlm.nih.gov/pubmed/27391331
http://dx.doi.org/10.1371/journal.pone.0158819
work_keys_str_mv AT webersusannenicole tlr4deficiencyprotectsagainsthepaticfibrosisanddiethylnitrosamineinducedprecarcinogenicliverinjuryinfibroticliver
AT bohnerannika tlr4deficiencyprotectsagainsthepaticfibrosisanddiethylnitrosamineinducedprecarcinogenicliverinjuryinfibroticliver
AT dapitodianneh tlr4deficiencyprotectsagainsthepaticfibrosisanddiethylnitrosamineinducedprecarcinogenicliverinjuryinfibroticliver
AT schwaberobertf tlr4deficiencyprotectsagainsthepaticfibrosisanddiethylnitrosamineinducedprecarcinogenicliverinjuryinfibroticliver
AT lammertfrank tlr4deficiencyprotectsagainsthepaticfibrosisanddiethylnitrosamineinducedprecarcinogenicliverinjuryinfibroticliver